Apr 16, 2024 | Press Releases
SARASOTA, Fla., April 16, 2024 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition...
Dec 11, 2023 | Press Releases
Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024NAYA expects to close its previously announced merger...
Dec 6, 2023 | Press Releases
NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA’s FLEX-NK™ bispecific antibodies and ONK’s optimally engineered natural killer (NK) cells for the treatment of...
Nov 28, 2023 | Press Releases
SARASOTA, Fla., Nov. 28, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and...
Nov 13, 2023 | Press Releases
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO)...
Nov 10, 2023 | Press Releases
SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO”), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. (“NAYA”), a...
